Document is current
Any future updates will be listed below
-
Authors
González-Lleó, Ana María
Brito-Casillas, Yeray
Martín-Santana, Virginia
Gil-Quintana, Yaiza
Tugores, Antonio
Scicali, Roberto
Riaño, Marta
Hernández-Baraza, Luisa
Jiménez-Monzón, Roberto
Girona, Josefa
Di Giacomo Barbagallo, Francesco
Masana, Luis
Boronat, Mauro
Wägner, Ana M.
Sánchez-Hernández, Rosa M.
-
Funding
Funding for this research was provided by:
Instituto de Salud Carlos III (CM19/00116, CM19/00116, CM19/00116)
Instituto de Salud Carlos III,Spain (PI 20/00846, PI 20/00846, PI 20/00846)
Fundación Canaria Instituto de Investigación Sanitaria de Canarias (PIFIISC 20/16, PIFIISC 20/16)
- License Information
-
More Information
Article History
Received: 25 March 2025
Accepted: 10 July 2025
First Online: 6 August 2025
Declarations
:
: The study was approved by the Gran Canaria ethics committee (Committee on Ethics and Research with Drugs of the Province of Las Palmas, Las Palmas de Gran Canaria, Spain; approval code: CEIm H.U.G.C. Dr. Negrín: 2020–164-1) and by the local Italian Ethics Committee, in accordance with the ethical standards of the institutional and national research committees. This study was conducted following the ethical principles outlined in the Declaration of Helsinki.
: Not applicable.
: The authors declare no competing interests.
